ADMA Biologics Inc $ADMA Shares Sold by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System lowered its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 51.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 34,306 shares of the biotechnology company’s stock after selling 35,854 shares during the period. Maryland State Retirement & Pension System’s holdings in ADMA Biologics were worth $503,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. Salomon & Ludwin LLC bought a new position in ADMA Biologics in the 3rd quarter worth about $25,000. Cullen Frost Bankers Inc. boosted its position in shares of ADMA Biologics by 112.5% during the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,081 shares during the period. Financial Consulate Inc. bought a new position in ADMA Biologics in the 3rd quarter worth approximately $44,000. Ameritas Advisory Services LLC acquired a new stake in ADMA Biologics in the 2nd quarter valued at approximately $46,000. Finally, Blue Trust Inc. raised its stake in ADMA Biologics by 53.6% during the 2nd quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 964 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $17.40 on Friday. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The stock has a market cap of $4.14 billion, a price-to-earnings ratio of 20.23 and a beta of 0.47. The stock’s 50 day moving average price is $18.47 and its 200 day moving average price is $17.10. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.13 and a quick ratio of 3.65.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.16. ADMA Biologics had a return on equity of 36.52% and a net margin of 42.87%.The firm had revenue of $134.22 million during the quarter, compared to analyst estimates of $131.20 million. During the same period last year, the company posted $0.15 EPS. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. Equities research analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, ADMA Biologics currently has a consensus rating of “Buy” and an average target price of $28.50.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.